David Headrick

(The following information was supplied by the firm)

Shareholder

David Headrick is a Shareholder at McAndrews with deep experience in both intellectual property litigation and advising clients on strategic intellectual property matters. David has tried and litigated many cases, some involving more than $2 billion in accused products. He is recognized by IAM Patent 1000 and according to IAM’s sources, “There’s nobody better to have by your side in strategic negotiations, critical conflict resolution or bet-the-company litigation than David.”

David’s practice also includes client counseling, intellectual property licensing, clearance opinions, intellectual property due diligence, and patent and trademark procurement.

Examples of David’s work include:

• Defending a large client when a competitor sought an emergency injunction against the client’s highest revenue-generating product and $1.2 billion in damages. The court denied the injunction, granted summary judgment, found the case “exceptional,” and awarded the client $5 million in attorney’s fees.
• Securing a $166 million victory for a large client. For a number of years, this case ranked in the top ten of all patent infringement awards in the U.S.
• Advising a medical device client in its $130 million acquisition of a company specializing in metal and synthetic products in the orthopedics, biologics, spine, trauma, and cardiothoracic markets.
• Guiding a consumer electronics client through the IP issues involved in its $72 million acquisition of a well-known electronic toy manufacturer.

David also has extensive experience with contested proceedings in the U.S. Patent Office and foreign patent jurisdictions (where he works closely with foreign counsel to defend clients’ global intellectual property interests).

In transactional work, David has advised numerous clients on intellectual property acquisition, divestiture, and licensing deals valued in the hundreds of millions of dollars.

David’s experience encompasses a broad spectrum of technologies, including medical devices, coronary angioplasty catheters, coronary stent systems, cardiac defibrillators/pacemakers, allograft surgical implants, bone cleaning and processing technology, mesenchymal stem cells, Wi-Fi and video encoding technology, digital electronics, software and operating systems, and needleless injection sites.